

**From:** [OC GCP Questions](#)  
**To:** [REDACTED]  
**Subject:** Biometrics for start-up question  
**Date:** Monday, May 18, 2015 12:15:59 PM

---

Good morning –

It is best to send your question directly to the Center for Drugs (CDER) as they are knowledgeable about treatment clinical trials. Their email address is [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)

Additionally, please see the links below that might be helpful to you.

[Search for FDA Guidance Documents > Treatment Use of Investigational Drugs - Information Sheet](#)

<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf>

[Code of Federal Regulations](#)

Kind regards,

Doreen M. Kezer, MSN  
Senior Health Policy Analyst  
Office of Good Clinical Practice  
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

---

**From:** [REDACTED]  
**Sent:** Monday, May 18, 2015 9:59 AM  
**To:** OC GCP Questions  
**Subject:** RE: Biometrics for start-up question

Hello,

On the FDA website, I am looking for recommendation or guidance on a site's start-up time for a treatment clinical trial. For example, some pharmaceutical sponsors have said the industry standard is 90 days which includes completion of budget, contract, and IRB approval.

Any information you can provide in a document or from a FAQ source would be appreciated.

Best Regards,

[REDACTED]